Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNC-109
- Development stage
- Phase 1
- Lead developer
- Simnova Biotherapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SNC-109 is an autologous CAR-T cell therapy developed for the treatment of recurrent glioblastoma multiforme. It is engineered to target multiple tumor-associated antigens, specifically EGFR, EGFRvIII, HER2, and IL-13Rα2. The mechanism involves the use of genetically modified T cells expressing chimeric antigen receptors that recognize and bind these targets on tumor cells, leading to targeted cytotoxicity. The therapy is being investigated in clinical trials for its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in patients with recurrent glioblastoma[1][4][7].
- Other names
- SNC-109SNC109SNC 109SNC109 injectionSNC-109 injectionSNC 109 injection
02
Targets
EGFR (Epidermal growth factor receptor)EGFRvIII (Epidermal growth factor receptor variant III)ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on SNC-109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNC-109.